At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study
In Brief
A Phase 3 clinical trial evaluating Metformin and Matching Placebo for Migraine. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartFeb 2016
Primary CompletionJun 2019
TodayJul 2026
First PostedOct 30, 2015
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.7 years ago
Interventions
Metformindrug
Metformin 500mg twice daily
Matching Placebodrug
Matching Placebo twice daily